Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study † † Note: This work was previously presented in part at the 2019 American Society of Clinical Oncology meeting (Abstract 3513) and at the 2020 American Society of Clinical Oncology-GI meeting (Abstract 10).
Titel:
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study † † Note: This work was previously presented in part at the 2019 American Society of Clinical Oncology meeting (Abstract 3513) and at the 2020 American Society of Clinical Oncology-GI meeting (Abstract 10).
Auteur:
Pagès, F. André, T. Taieb, J. Vernerey, D. Henriques, J. Borg, C. Marliot, F. Ben Jannet, R. Louvet, C. Mineur, L. Bennouna, J. Desrame, J. Faroux, R. Kirilovsky, A. Duval, A. Laurent-Puig, P. Svrcek, M. Hermitte, F. Catteau, A. Galon, J. Emile, J.-F.